Tibet Duo Rui Pharmaceutical (301075.SZ) is planning to sell up to 1,044,500 shares of repurchased stock.

Doray Pharmaceutical (301075.SZ) announced that the Board of Directors has approved the "Proposal on the Plan for Selling Repurchased Shares through Centralized Bidding for Reduction". In accordance with the purposes stipulated in the "Repurchase Report" disclosed by the company on February 8, 2024, the company has agreed to sell the repurchased shares through centralized bidding, with the implementation period being within 6 months after 15 trading days from the date of this announcement (from January 14, 2026 to July 13, 2026, excluding the period prohibited for selling according to the relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange). The planned sale of repurchased shares this time will not exceed 1,044,500 shares, accounting for 1.31% of the company's total share capital, and the selling price will be determined based on the secondary market price.